drugset / Trial / NCT06312787

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

NCT06312787

Phase 1 Completed 15 enrolled Vertex Pharmaceuticals Incorporated
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability, effect of food on the pharmacokinetic parameters, and safety and tolerability, of a tablet formulation of VX-118 in healthy participants.

Timeline

Start
2024-04-02
Primary completion
2024-05-04
Completion
2024-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-118 Unknown Oral

Indications